 Connection
Kyle Molina to Adult
This is a "connection" page, showing publications Kyle Molina has written about Adult.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.232 |
|
|
|
-
Molina KC, Webb BJ, Kennerley V, Beaty LE, Bennett TD, Carlson NE, Mayer DA, Peers JL, Russell S, Wynia MK, Aggarwal NR, Ginde AA. Real-world evaluation of early remdesivir in high-risk COVID-19 outpatients during Omicron including BQ.1/BQ.1.1/XBB.1.5. BMC Infect Dis. 2024 Aug 08; 24(1):802.
Score: 0.047
-
Molina KC, Kennerley V, Beaty LE, Bennett TD, Carlson NE, Mayer DA, Peers JL, Russell S, Wynia MK, Aggarwal NR, Ginde AA. Real-world evaluation of bebtelovimab effectiveness during the period of COVID-19 Omicron variants, including BA.4/BA.5. Int J Infect Dis. 2023 Jul; 132:34-39.
Score: 0.043
-
Molina KC, Hall ST, Barletta JF, Mangram AJ, Dzandu JK, Huang V. Utilization of Augmented Renal Clearance in Trauma Intensive Care Scoring System to Improve Vancomycin Dosing in Trauma Patients at Risk for Augmented Renal Clearance. Surg Infect (Larchmt). 2020 Feb; 21(1):43-47.
Score: 0.033
-
Molina KC, Barletta JF, Hall ST, Yazdani C, Huang V. The Risk of Acute Kidney Injury in Critically Ill Patients Receiving Concomitant Vancomycin With Piperacillin-Tazobactam or Cefepime. J Intensive Care Med. 2020 Dec; 35(12):1434-1438.
Score: 0.032
-
Xiao M, Molina KC, Aggarwal NR, Beaty LE, Bennett TD, Carlson NE, Fish LE, Hamer MK, Kwan BM, Mayer DA, Peers JL, Wynia MK, Ginde AA. A Machine Learning Method for Allocating Scarce COVID-19 Monoclonal Antibodies. JAMA Health Forum. 2024 Sep 06; 5(9):e242884.
Score: 0.012
-
Scherger SJ, Molina KC, Palestine AG, Pecen PE, Bajrovic V. Cytomegalovirus Retinitis in the Modern Era of Solid Organ Transplantation. Transplant Proc. 2024 Sep; 56(7):1696-1701.
Score: 0.012
-
Jenrette JE, Coronato K, Miller MA, Molina KC, Quinones A, Jacknin G. Prospective evaluation of single-dose aminoglycosides for treatment of complicated cystitis in the emergency department. Acad Emerg Med. 2024 07; 31(7):649-655.
Score: 0.011
-
Texidor WM, Miller MA, Molina KC, Krsak M, Calvert B, Hart C, Storer M, Fish DN. Oritavancin as sequential therapy for Gram-positive bloodstream infections. BMC Infect Dis. 2024 Jan 24; 24(1):127.
Score: 0.011
-
Aggarwal NR, Molina KC, Beaty LE, Bennett TD, Carlson NE, Mayer DA, Peers JL, Russell S, Wynia MK, Ginde AA. Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study. Lancet Infect Dis. 2023 06; 23(6):696-705.
Score: 0.011
-
Aggarwal NR, Beaty LE, Bennett TD, Carlson NE, Mayer DA, Molina KC, Peers JL, Russell S, Wynia MK, Ginde AA. Change in effectiveness of sotrovimab for preventing hospitalization and mortality for at-risk COVID-19 outpatients during an Omicron BA.1 and BA.1.1-predominant phase. Int J Infect Dis. 2023 Mar; 128:310-317.
Score: 0.010
-
Johnson TM, Molina KC, Miller MA, Kiser TH, Huang M, Mueller SW. Combination ceftaroline and daptomycin salvage therapy for complicated methicillin-resistant Staphylococcus aureus bacteraemia compared with standard of care. Int J Antimicrob Agents. 2021 Apr; 57(4):106310.
Score: 0.009
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|